ARMR Sciences Launches $30M Capital Raise for Biodefense Platform

ARMR Sciences Inc. has announced a $30 million capital raise to advance its biodefense platform against fentanyl and AI-driven synthetic drug threats, as stated in a press release. The company is offering a private placement of Series A-1, 7% Convertible Preferred Stock, with the potential to increase the offering size to $50 million.

ARMR's lead product, ARMR-100, is an immunotherapy designed to provide annual protection against fentanyl. Developed at the University of Houston, the formulation has shown promising results in animal studies, preventing 92% of fentanyl from entering the brain and blocking its effects. The company plans to translate these results into human trials in collaboration with the Center for Human Drug Research.

The capital raise is part of ARMR's strategy to develop solutions for both military and civilian use, aiming to prevent synthetic drug overdoses before they occur. The company also plans to establish ARMR Defense Labs, a division focused on using AI for drug discovery to counter emerging synthetic threats.